logo-loader
view712 North

712 North excited to be funded by the National Institute of Health

712 North CEO Marcel V. Alavi spoke with Proactive at the Bio Investor Forum in San Francisco. 
Privately-held 712 North is an early-stage biotech developing personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: XPhyto sees Germany as key market as they announce deal with...

XPhyto (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers and Bunker, Managing Director Wolfgang Probst joined Steve Darling from Proactive Vancouver to share news the company has signed a deal with German Brewer Oettinger development, production, and distribution of cannabis-infused beverages and...

2 days, 9 hours ago

2 min read